Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
18 Years
N/A
Both
Cancer
Trial Information
Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment
80 patients will be included in swiss-romande hospitals and private oncologists and followed
by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration
is 48 weeks, with a motivational interviewing at least every three months. Patient adherence
will be assessed electronically by MEMS (Medication Event Monitoring System).
Inclusion Criteria:
- 18 years and older
- Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib,
nilotinib, everolimus, deferasirox)
- French speaking
Exclusion Criteria:
- None
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Change in Medication adherence
Outcome Description:
MEMS data, completed by informations given in motivational interviewing
Outcome Time Frame:
3 months, 6 months, 9 months, 12 months
Safety Issue:
No
Principal Investigator
Bugnon Olivier, Professor
Investigator Role:
Study Chair
Investigator Affiliation:
Policlinique Médicale Universitaire
Authority:
Switzerland: Ethikkommission
Study ID:
139/10
NCT ID:
NCT01370980
Start Date:
July 2010
Completion Date:
September 2014
Related Keywords:
- Cancer
- Medication Adherence
- Patient Compliance
- Patient Acceptance of Health Care
- Administration, Oral
- Cancer
- Letrozol
- Exemestan
- Imatinib
- Sunitinib
- Nilotinib
- Everolimus
- Deferasirox
- Mouth Neoplasms
Name | Location |
|---|
